Recce Pharmaceuticals Ltd (FRA:R9Q)

Germany flag Germany · Delayed Price · Currency is EUR
0.304
0.00 (0.00%)
Last updated: Dec 4, 2025, 8:03 AM CET
17.83%
Market Cap 101.38M
Revenue (ttm) 4.19M
Net Income (ttm) -11.96M
Shares Out n/a
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,000
Average Volume n/a
Open 0.304
Previous Close 0.304
Day's Range 0.304 - 0.304
52-Week Range 0.129 - 0.304
Beta n/a
RSI 79.50
Earnings Date Nov 26, 2025

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infect... [Read more]

Industry Pharmaceutical Preparations
Founded 2007
Country Australia
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol R9Q
Full Company Profile

Financial Performance

In 2025, Recce Pharmaceuticals's revenue was 7.51 million, an increase of 49.33% compared to the previous year's 5.03 million. Losses were -21.43 million, 21.3% more than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.